Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.7.7 (
DNA polymerase
)
17,007
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
In all trypanosomatids, trans splicing of the spliced leader (SL) RNA is a required step in the maturation of all nucleus-derived mRNAs. The SL RNA is transcribed with an oligo-U 3' extension that is removed prior to trans splicing. Here we report the identification and characterization of a nonexosomal, 3'-->5' exonuclease required for SL RNA 3'-end formation in Trypanosoma brucei. We named this enzyme
SNIP
(for snRNA incomplete 3' processing). The central 158-amino-acid domain of
SNIP
is related to the exonuclease III (ExoIII) domain of the 3'-->5' proofreading epsilon subunit of Escherichia coli
DNA polymerase III
holoenzyme.
SNIP
had a preference for oligo(U) 3' extensions in vitro. RNA interference-mediated knockdown of
SNIP
resulted in a growth defect and correlated with the accumulation of one- to two- nucleotide 3' extensions of SL RNA, U2 and U4 snRNAs, a five-nucleotide extension of 5S rRNA, and the destabilization of U3 snoRNA and U2 snRNA.
SNIP
-green fluorescent protein localized to the nucleoplasm, and substrate SL RNA derived from
SNIP
knockdown cells showed wild-type cap 4 modification, indicating that
SNIP
acts on SL RNA after cytosolic trafficking. Since the primary SL RNA transcript was not the accumulating species in
SNIP
knockdown cells, SL RNA 3'-end formation is a multistep process in which
SNIP
provides the ultimate 3'-end polishing. We speculate that
SNIP
is part of an organized nucleoplasmic machinery responsible for processing of SL RNA.
...
PMID:3'-End polishing of the kinetoplastid spliced leader RNA is performed by SNIP, a 3'-->5' exonuclease with a Motley assortment of small RNA substrates. 1554 46